Guardant Health (GH) to Release Quarterly Earnings on Wednesday

Guardant Health (NASDAQ:GH) is projected to release its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect Guardant Health to post earnings of ($0.48) per share and revenue of $235.7150 million for the quarter. Guardant Health has set its FY 2025 guidance at EPS.Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

Guardant Health (NASDAQ:GH) last issued its earnings results on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.08. The firm had revenue of $232.09 million during the quarter, compared to analyst estimates of $211.19 million. Guardant Health’s revenue was up 31.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.84) EPS. On average, analysts expect Guardant Health to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Guardant Health Trading Down 3.8%

Shares of GH opened at $67.51 on Wednesday. The firm has a market cap of $8.42 billion, a price-to-earnings ratio of -20.15 and a beta of 1.53. The stock has a 50 day moving average of $61.62 and a 200-day moving average of $51.28. Guardant Health has a 52 week low of $20.14 and a 52 week high of $70.33.

Analysts Set New Price Targets

Several brokerages have recently commented on GH. JPMorgan Chase & Co. lifted their target price on Guardant Health from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Evercore ISI lifted their target price on Guardant Health from $60.00 to $68.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. William Blair reiterated an “outperform” rating on shares of Guardant Health in a research report on Thursday, September 25th. Stifel Nicolaus set a $73.00 target price on Guardant Health in a research report on Thursday, September 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Wednesday, October 8th. Twenty-three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Guardant Health has a consensus rating of “Moderate Buy” and a consensus price target of $65.86.

Insiders Place Their Bets

In other news, Director Medina Manuel Hidalgo sold 2,165 shares of the business’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $54.16, for a total value of $117,256.40. Following the sale, the director owned 851 shares of the company’s stock, valued at approximately $46,090.16. The trade was a 71.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Helmy Eltoukhy sold 300,000 shares of the business’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total value of $17,835,000.00. Following the completion of the sale, the chief executive officer directly owned 2,123,499 shares in the company, valued at $126,242,015.55. This represents a 12.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 302,691 shares of company stock worth $17,984,628 in the last three months. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors and hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company raised its position in shares of Guardant Health by 9.4% during the second quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock worth $32,922,000 after purchasing an additional 54,284 shares during the period. Cubist Systematic Strategies LLC raised its position in shares of Guardant Health by 451.2% during the second quarter. Cubist Systematic Strategies LLC now owns 329,322 shares of the company’s stock worth $17,138,000 after purchasing an additional 269,575 shares during the period. Engineers Gate Manager LP raised its position in shares of Guardant Health by 13.6% during the second quarter. Engineers Gate Manager LP now owns 277,551 shares of the company’s stock worth $14,444,000 after purchasing an additional 33,167 shares during the period. Raymond James Financial Inc. raised its position in shares of Guardant Health by 266.4% during the second quarter. Raymond James Financial Inc. now owns 232,599 shares of the company’s stock worth $12,104,000 after purchasing an additional 169,110 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Guardant Health by 56.4% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock valued at $5,800,000 after buying an additional 40,209 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.